Key result
Dapagliflozin linked to ~29-point higher rate of effective blood pressure reduction in T2D.
Why the study?
This study was conducted to evaluate the efficacy of SGLT2 inhibitors in managing blood pressure in patients with type 2 diabetes and hypertension.
Does adding dapagliflozin 10 mg once daily to standard therapy improve blood pressure reduction at 12 weeks in adults with type 2 diabetes mellitus and hypertension?
Does adding dapagliflozin 10 mg once daily to standard therapy improve blood pressure reduction at 12 weeks in adults with type 2 diabetes mellitus and hypertension?
Answers are grounded in this paper and cite their sources.
Adding dapagliflozin 10 mg daily to standard therapy in patients with type 2 diabetes and hypertension significantly increased the proportion of patients achieving effective blood pressure reduction at 12 weeks compared to standard therapy alone (78.2% vs. 49.1%, p<0.001).
Objectives: To evaluate the efficacy of SGLT2 inhibitors in managing blood pressure in patients with type 2 diabetes and hypertension. Materials and Methods: After ethical approval and informed consent, 220 eligible patients were enrolled and equally allocated into two groups. Group A received dapagliflozin (10 mg once daily) plus standard therapy, while Group B received standard treatment alone. Baseline demographic and clinical data were collected using a structured questionnaire, and patients were followed for 3 months. Blood pressure was measured at baseline and after 12 weeks to assess efficacy, defined as a reduction of ≥5 mmHg in systolic and/or ≥3 mmHg in diastolic blood pressure. Data were analyzed using SPSS version 25. Results: The mean age was 54.3±7.87 years in Group A and 56.5±7.91 years in Group B. Overall treatment effectiveness was significantly higher in Group A than in Group B (78.2% vs. 49.1%, p<0.001). Stratified analysis also showed significantly greater effectiveness with dapagliflozin across most age, gender, duration of hypertension, duration of diabetes, and BMI subgroups, except among patients with hypertension >10 years, diabetes duration of 1–5 years, and normal BMI, where the differences were not statistically significant. Conclusion: It was concluded that the addition of dapagliflozin to standard therapy was more effective than standard treatment alone in reducing blood pressure in patients with type 2 diabetes mellitus and hypertension. Dapagliflozin may provide additional metabolic and cardiovascular benefits, although larger multicenter studies with longer follow-up are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Safdar et al. (2026) studied Type 2 diabetes mellitus and hypertension (n=220). Dapagliflozin plus standard therapy vs. Standard antidiabetic and antihypertensive therapy alone was evaluated on Treatment effectiveness defined as a reduction of >= 5 mmHg in systolic blood pressure and/or >= 3 mmHg in diastolic blood pressure at 12 weeks (p=<0.001). Dapagliflozin daily added to standard therapy achieved effective blood pressure reduction in 78.2% of patients with type 2 diabetes and hypertension vs 49.1% with standard care.
Synapse has enriched 10 related papers. Consider them for comparative context: